<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0472CBD7-47BA-4C81-BDAF-F83E8C090B06"><gtr:id>0472CBD7-47BA-4C81-BDAF-F83E8C090B06</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Newstead</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900399"><gtr:id>5EC61F63-C28C-42C3-985A-A2C3357AC55D</gtr:id><gtr:title>Elucidating the molecular mechanism of drug transport through structural studies of peptide transport proteins.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0900399</gtr:grantReference><gtr:abstractText>The design of drugs for oral administration is common practice in the pharmaceutical industry due to ease of patient administration, storage, distribution and patient compliance. Many drugs however are poorly absorbed in the gastrointestinal (GI) tract, the main route by which orally administered drugs enter the blood stream. One successful approach to overcome this obstacle has been the design of prodrugs. Prodrugs are modified drug compounds that target nutrient transporters in the GI tract. Of these, oligopeptide transporters are the most promising targets as they are highly expressed in the GI tract and are already responsible for the uptake of antibiotics. This prodrug strategy has already been successful in improving the oral bioavailability of a number of medically important antivirals. The role of this research proposal is to gain an understanding of the underlying mechanism by which these peptide transporters function. Such information will enable a more rational extension of the initial prodrug approach with benefits for both patients and the pharmaceutical industry alike.</gtr:abstractText><gtr:technicalSummary>The proton oligopeptide cotransporter family, SLC15, is a family of integral membrane proteins that utilise the proton motive force to power the uptake of short chain peptides and peptidomimetics into a variety of cells. These proteins are the major routes of dietry nitrogen absorption from the small intestine and nitrogen re-absorption from the glomerular filtrate in the kidney. They are of broad pharmaceutical interest due to their ability to actively uptake a number of pharmaceutically important drugs, such as the beta-lactam antibiotics, certain antivirals and HIV protease inhibitors. 
The aim of this proposal is to elucidate the molecular mechanism by which the SLC15 family of integral membrane proteins function and to gain a deeper understanding of drug transport and oral bioavailability. This research has significant clinical utility, as oral administration is currently the most successful route for drug administration. An understanding, at the molecular level, of how drugs are both recognised and transported across the gut epithelium will aid in more rational drug design and should have significant translational potential.
I plan to achieve these goals principally through the insights gained from X-ray crystallography. X-ray crystallography is particularly powerful in this regard as it allows currently unparalleled insights into molecular form and function. Functional studies will also be undertaken and directed by the insights obtained from the structural models. This will be a collaborative project with both eukaryotic and prokaryotic transporters being studied.
Using the expertise I have gained in the laboratory of Prof. So Iwata I am currently in the process of determining the first crystal structure of a peptide transport protein. The insights gained from this structure will make a significant contribution to our understanding of drug uptake in the human gastrointestinal tract. Through collaborations with medicinal chemists and physiologists I plan to extend this research to include the human members of this transport family. During my post-doctoral research I helped develop a rational platform for optimising membrane protein transporters for structural studies. This included screening for solubility, monodispersity and thermal stability in different detergents using small quantities of protein to allow rapid and cost effective identification of suitable targets. These methods have worked successfully for the bacterial peptide transport proteins and I now plan to utilise these methods to work on the mammalian SLC15 family members.</gtr:technicalSummary><gtr:fund><gtr:end>2014-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>853620</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kyoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Graduate School of Medicine and Faculty of Medicine, Kyoto University</gtr:department><gtr:description>High resolution crystal structures of plasma membrane drug/peptide transporters.</gtr:description><gtr:id>E2C55204-28C6-4DA2-B244-EFAA92107BE9</gtr:id><gtr:impact>A number of monoclonals have been made and are currently in co-crystallisation trials.</gtr:impact><gtr:outcomeId>SMdgLAyCskM-1</gtr:outcomeId><gtr:partnerContribution>Our partners have used these proteins to raise mono clonal antibodies for co-crystallisation studies.</gtr:partnerContribution><gtr:piContribution>We have provided highly pure and stable eukaryotic peptide transport proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>13500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Research Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>7979F3EA-DEA7-43AE-B287-B005DF68889C</gtr:id><gtr:outcomeId>Qr4k5UtqQTV</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Research Grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>5362A13C-81D0-4AA1-8B7A-857202DF4459</gtr:id><gtr:outcomeId>EasZidsCpVT0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society International Exchanges Scheme</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>C672DC4D-CF1D-445F-B527-C58BD7F85CC1</gtr:id><gtr:outcomeId>pzWy4LYBjaw</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Unique screen for the purpose of identifying crystallisation conditions for membrane proteins.</gtr:description><gtr:grantRef>G0900399</gtr:grantRef><gtr:id>3BAF4038-1E57-41D0-8DD2-35697534FA6C</gtr:id><gtr:impact>n/a.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>UFn1GkvECL3</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>MemGold2: Membrane Protein Crystallisation Screen</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Development of an additive screen for membrane protein crystallisation. Currently marketed through a UK biotech company, Molecular Dimensions Ltd.</gtr:description><gtr:grantRef>G0900399</gtr:grantRef><gtr:id>947D0181-A0CA-4011-9302-EF230C8C850B</gtr:id><gtr:impact>n/a</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>dRmCJQsAHeA</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>MemAdvantage</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>MemGold2 is the most up to date screen for the crystallisation of membrane proteins for structural study. The screen was developed in partnership with Molecular Dimensions Ltd. a UK biotech company, and is currently on sale worldwide through their distributors. This development was funded through my MRC CDA.</gtr:description><gtr:id>2B2E2D21-D6E8-4DA2-BD5B-A4C5AC0F7F42</gtr:id><gtr:impact>Still at early stage, but the screen should accelerate research into medically important membrane protein targets.</gtr:impact><gtr:outcomeId>aAzLdJMC94L</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MemGold2 Crystallisation Screen for Membrane Proteins</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Membrane Protein additive screen for crystal optimisation.</gtr:description><gtr:id>7C425DEF-F2DA-4ECA-9DF4-10B1090AFE69</gtr:id><gtr:impact>still at early stage.</gtr:impact><gtr:outcomeId>digB734qV2P</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MemAdvantage</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:url>http://www.moleculardimensions.com/shopdisplayproducts.asp?id=212&amp;cat=Membrane+Protein+Additive+Kits</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have collated together information on the crystallisation of all alpha helical membrane proteins in the Protein Data Bank upto 2012.</gtr:description><gtr:id>BB80C783-D493-4BE9-A20A-F4D3FAEC0921</gtr:id><gtr:impact>We have developed a new membrane protein crystallisation screen that we are currently in the process of developing with a commercial company, Molecular Dimension Ltd.</gtr:impact><gtr:outcomeId>d41nbDEjxd5</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Membrane Protein Crystallisation data</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Molecular Dimension Ltd.</gtr:companyName><gtr:description>http://www.moleculardimensions.com/</gtr:description><gtr:id>421CB63D-9B26-4C91-A339-A9F21150E1B6</gtr:id><gtr:impact>Molecular Dimensions is a world leading supplier of screens, reagents and instrumentation for protein structure determination by X-ray crystallography. Including: modern crystallization screens and reagents, bacterial growth expression media, ready-to-use selenomethioine expression media, SWISSCI MRC 2 Well and 3 Well Crystallization Plates, 24-well crystallization plates, LaminexTM, cryocrystallography products, ESRF/EMBL sample changer kits and accessories, and a range of instrumentation for protein crystal growth and analysis.</gtr:impact><gtr:outcomeId>H1Rqph9gDtf</gtr:outcomeId><gtr:url>http://www.moleculardimensions.com/</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>CD7F8D8B-8CDB-4583-9B6B-C75FD4AB05BA</gtr:id><gtr:title>Capsaicin interaction with TRPV1 channels in a lipid bilayer: molecular dynamics simulation.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bd67b3d874d816abe9201eeae4e609"><gtr:id>a3bd67b3d874d816abe9201eeae4e609</gtr:id><gtr:otherNames>Hanson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>doi_55f9859851074b29</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>737BFB30-3E6D-42D3-9CC1-9D1870F5A2E5</gtr:id><gtr:title>Benchmarking membrane protein detergent stability for improving throughput of high-resolution X-ray structures.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44e1f3988a54c6cbe487df4432c4dc7e"><gtr:id>44e1f3988a54c6cbe487df4432c4dc7e</gtr:id><gtr:otherNames>Sonoda Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>LyYf5jtr5nj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4751A8BC-8A3C-4BB2-AE46-BB77526FA96E</gtr:id><gtr:title>Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eb60e0951a3926f5ee280673774b13c"><gtr:id>3eb60e0951a3926f5ee280673774b13c</gtr:id><gtr:otherNames>Newstead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>M1QYHFQGsbx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C86545B-8DA3-4064-9B3B-C9AAA2CFF410</gtr:id><gtr:title>Towards a structural understanding of drug and peptide transport within the proton-dependent oligopeptide transporter (POT) family.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eb60e0951a3926f5ee280673774b13c"><gtr:id>3eb60e0951a3926f5ee280673774b13c</gtr:id><gtr:otherNames>Newstead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>VTLque23UnE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3BBA1BE-08D9-4F47-A9F9-87B1071550B5</gtr:id><gtr:title>Phasing statistics for alpha helical membrane protein structures.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02efa49a825789e6df5d4d025f8eaa9f"><gtr:id>02efa49a825789e6df5d4d025f8eaa9f</gtr:id><gtr:otherNames>Parker JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>pm_14130_20_23963889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708726DD-CD9C-4583-835D-9743F92D1B39</gtr:id><gtr:title>Current trends in a-helical membrane protein crystallization: an update.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02efa49a825789e6df5d4d025f8eaa9f"><gtr:id>02efa49a825789e6df5d4d025f8eaa9f</gtr:id><gtr:otherNames>Parker JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>pm_14130_20_22811290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB998E71-2D2A-42B6-B4DA-C073AA6C35DE</gtr:id><gtr:title>Structural basis for polyspecificity in the POT family of proton-coupled oligopeptide transporters.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d149fa95dcf98598de1369eb3317a914"><gtr:id>d149fa95dcf98598de1369eb3317a914</gtr:id><gtr:otherNames>Lyons JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>doi_55f9859851197a34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>673BDE1E-A771-43E3-AAB8-AF6535E60E7F</gtr:id><gtr:title>Structural basis for dynamic mechanism of proton-coupled symport by the peptide transporter POT.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43569fafde59caaa2f4e41da849dd46b"><gtr:id>43569fafde59caaa2f4e41da849dd46b</gtr:id><gtr:otherNames>Doki S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14130_20_23798427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E8E904C-455A-473E-8BA2-7F396A27D412</gtr:id><gtr:title>Gating topology of the proton-coupled oligopeptide symporters.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43a6b643d6c14a13bc6b763d401a76b5"><gtr:id>43a6b643d6c14a13bc6b763d401a76b5</gtr:id><gtr:otherNames>Fowler PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>doi_55f985985110b7df</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7706DA8-31FA-4C80-A926-6ECEE945C8D2</gtr:id><gtr:title>MemProtMD: Automated Insertion of Membrane Protein Structures into Explicit Lipid Membranes.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a807eff7a6f8b2dc6e13baea9674e0a"><gtr:id>5a807eff7a6f8b2dc6e13baea9674e0a</gtr:id><gtr:otherNames>Stansfeld PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>56cb2a28308f60.51152591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>601172C4-2BC6-4916-9925-7515EE92BAB1</gtr:id><gtr:title>Method to increase the yield of eukaryotic membrane protein expression in Saccharomyces cerevisiae for structural and functional studies.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02efa49a825789e6df5d4d025f8eaa9f"><gtr:id>02efa49a825789e6df5d4d025f8eaa9f</gtr:id><gtr:otherNames>Parker JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>585d59ca734ad3.02459781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F88CC5-9373-4F83-88EF-D648B9D18FB4</gtr:id><gtr:title>Overcoming barriers to membrane protein structure determination.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/affc477b16c011ace6a096118cb529cf"><gtr:id>affc477b16c011ace6a096118cb529cf</gtr:id><gtr:otherNames>Bill RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>sECb5qNPNyy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD06FC3E-8C25-4F34-912B-5044A0A84FD2</gtr:id><gtr:title>A two-domain elevator mechanism for sodium/proton antiport.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ffb24d3ccf4afc20a2ffdb9e1f11a63"><gtr:id>7ffb24d3ccf4afc20a2ffdb9e1f11a63</gtr:id><gtr:otherNames>Lee C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_14130_20_23995679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>344BB0FB-E859-4238-A569-1E9D5835262E</gtr:id><gtr:title>Membrane protein structure determination - the next generation.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69542a1bf73d127ce281cc2c89caaa41"><gtr:id>69542a1bf73d127ce281cc2c89caaa41</gtr:id><gtr:otherNames>Moraes I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_14130_20_23860256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BBE739D-F74A-4B47-917D-727B12EB2E9F</gtr:id><gtr:title>Crystal Structures of the Extracellular Domain from PepT1 and PepT2 Provide Novel Insights into Mammalian Peptide Transport.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8eda91afb7201d6df8f785a4ad17d4d6"><gtr:id>8eda91afb7201d6df8f785a4ad17d4d6</gtr:id><gtr:otherNames>Beale JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>585d579bb06004.50393254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FBBA4B7-DDDD-4E73-8EE0-34831D61B936</gtr:id><gtr:title>Molecular basis of nitrate uptake by the plant nitrate transporter NRT1.1.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02efa49a825789e6df5d4d025f8eaa9f"><gtr:id>02efa49a825789e6df5d4d025f8eaa9f</gtr:id><gtr:otherNames>Parker JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_540e169e169c3e0a5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31B48179-E896-4F5F-A96B-060429E56FAC</gtr:id><gtr:title>Alternating access mechanism in the POT family of oligopeptide transporters.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/142598a64831cbc258e79adc19ec9310"><gtr:id>142598a64831cbc258e79adc19ec9310</gtr:id><gtr:otherNames>Solcan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_14130_20_22659829</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900399</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>